Critical Care Pharmacist Attitudes and Perceptions of Neuromuscular Blocker Infusions in ARDS.

John W DevlinSarah E TrainKaren E A BurnsAnthony MassaroTing Ting WuTimothy CastorJohn VassaurKavitha SelvanJohn P KressBrian L Erstad

Published in: The Annals of pharmacotherapy (2023)

Current critical care pharmacists believe NMBI for ARDS patients are best reserved until after trials of deep sedation or proning; unique considerations exist in COVID+ patients. Our results should be considered when ICU NMBI protocols are being developed and bedside decisions regarding NMBI use in ARDS are being formulated.

Keyphrases

mechanical ventilation
acute respiratory distress syndrome
extracorporeal membrane oxygenation
intensive care unit
end stage renal disease
ejection fraction
healthcare
sars cov
primary care
prognostic factors